1.Erratum to: Corrigendum: 2023 Korean Society of Menopause -Osteoporosis Guidelines Part I
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(3):179-179
2.Erratum to: Corrigendum: 2023 Korean Society of Menopause -Osteoporosis Guidelines Part I
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(3):179-179
3.Erratum to: Corrigendum: 2023 Korean Society of Menopause -Osteoporosis Guidelines Part I
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(3):179-179
4.The 2024 Guidelines for Osteoporosis - Korean Society of Menopause
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong- Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(1):1-23
5.The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(2):55-77
6.Corrigendum: 2023 Korean Society of Menopause - Osteoporosis Guidelines Part I
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(2):126-126
7.Etiology and Secular Trends in Primary Amenorrhea in 856 Patients: A 17-Year Retrospective Multicenter Study in Korea
Hoon KIM ; Mee-Hwa LEE ; Dong-Yun LEE ; Hyein KIM ; Hyun Jung LEE ; Miran KIM ; Joo Hyun PARK ; Bo Hyon YUN ; Sa Ra LEE ; Hyun Hee CHO ; Byung Moon KANG
Journal of Korean Medical Science 2022;37(29):e230-
Background:
This study was performed to evaluate etiologies and secular trends in primary amenorrhea in South Korea.
Methods:
This retrospective multi-center study analyzed 856 women who were diagnosed with primary amenorrhea between 2000 and 2016. Clinical characteristics were compared according to categories of amenorrhea (hypergonadotropic/hypogonadotropic hypogonadism, eugonadism, disorders of sex development) or specific causes of primary amenorrhea. In addition, we assessed secular trends of etiology and developmental status based on the year of diagnosis.
Results:
The most frequent etiology was eugonadism (39.8%). Among specific causes, Müllerian agenesis was most common (26.2%), followed by gonadal dysgenesis (22.4%). Women with hypergonadotropic hypogonadism were more likely to have lower height and weight, compared to other categories. In addition, the proportion of cases with iatrogenic or unknown causes increased significantly in hypergonadotropic hypogonadism category, but overall, no significant secular trends were detected according to etiology. The proportion of anovulation including polycystic ovarian syndrome increased with time, but the change did not reach statistical significance.
Conclusion
The results of this study provide useful clinical insight on the etiology and secular trends of primary amenorrhea. Further large-scale, prospective studies are necessary.
8.A New Thermo-Responsive Hyaluronic Acid Sol-Gel to Prevent Intrauterine Adhesions after Hysteroscopic Surgery: A Randomized, Non-Inferiority Trial
Dong-Yun LEE ; Sa Ra LEE ; Seul Ki KIM ; Jong Kil JOO ; Woo Shun LEE ; Jung-Ho SHIN ; SiHyun CHO ; Joon Cheol PARK ; Sung Hoon KIM
Yonsei Medical Journal 2020;61(10):868-874
Purpose:
To investigate the efficacy and safety of a newly developed thermo-responsive sol-gel, ABT13107, for reducing the formation of intrauterine adhesions (IUAs) after hysteroscopic surgery.
Materials and Methods:
In this multicenter, prospective, randomized trial (Canadian Task Force classification I), 192 women scheduled to undergo a hysteroscopic surgery at one of the eight university hospitals in South Korea were randomized into the ABT13107 group or the comparator (Hyalobarrier ® ) group in a 1:1 ratio. During hysteroscopic surgery, ABT13107 or Hyalobarrier® was injected to sufficiently cover the entire intrauterine cavity.
Results:
The patients returned to their respective sites for safety assessments at postoperative weeks 1 and 4 and for efficacy assessments at postoperative week 4. The post-surgery incidence of IUAs was 23.4% in the ABT13107 group and 25.8% in the comparator group; this difference met the criteria for ABT13107 to be considered as not inferior to the comparator. No differences were found in the extent of adhesions, types of adhesions, or the cumulative American Fertility Society score between the two treatment groups. Most adverse events were mild in severity, and no serious adverse events occurred.
Conclusion
ABT13107, a new anti-adhesive barrier containing hyaluronic acid, was not inferior to the highly viscous hyaluronic acid anti-adhesive barrier, Hyalurobarrier® in IUA formation after hysteroscopic surgery (Clinical trial registration No. NCT 04007211).
9.A multicenter cross-sectional study on the prevalence of overactive bladder and its impacts on the quality of life in gynecologic outpatients
Do Young KIM ; Da Hae JANG ; Hyun Jin KIM ; Sa Ra LEE ; Myung Jae JEON ; Jung Ho SHIN ; Hee Dong CHAE
Obstetrics & Gynecology Science 2020;63(2):181-186
OBJECTIVE: The present study assessed the prevalence of overactive bladder (OAB) symptoms in gynecologic outpatients and the effects of OAB on a patient's quality of life.METHODS: The survey was completed by adult female patients who visited the gynecology clinic for examination or treatment of gynecologic conditions. The subjects who met the exclusion criteria were excluded. The survey included a questionnaire assessing general characteristics, the purpose of the visit, diagnosis, and the presence or absence of OAB. The subjects were asked whether they were under medical treatment for OAB symptoms, and the degree of discomfort in daily activities was evaluated.RESULTS: In total, 1,990 female subjects visiting the gynecology clinics of 4 different institutions were recruited. On OAB Symptom Score, 188 subjects responded with scores of ≥2 for question #3 (≥1 time(s) weekly). The severity of OAB symptoms was as follows: 345 subjects had mild OAB, 127 subjects had moderate OAB, and 12 subjects had severe OAB. The prevalence of OAB symptoms was 10.30%.CONCLUSION: The present study confirmed that OAB symptoms are common, with a prevalence of 10.30%. Patients with OAB symptoms frequently neglect to seek medical intervention. Our findings will help inform patients to recognize their condition and seek medical assistance, especially in gynecologic outpatient clinics.
10.Comparison of treatment delay associated with tunneled hemodialysis catheter placement between interventionists.
Yoo Hyung KIM ; Hae Ri KIM ; Hong Jae JEON ; Ye Jin KIM ; Sa Ra JUNG ; Dae Eun CHOI ; Kang Wook LEE ; Ki Ryang NA
The Korean Journal of Internal Medicine 2016;31(3):543-551
BACKGROUND/AIMS: Fragmented care in nephrology can cause treatment delays. Nephrologists are qualified to perform vascular access-related procedures because they understand the pathophysiology of renal disease and perform physical examination for vascular access. We compared treatment delays associated with tunneled hemodialysis catheter (TDC) placement between interventional radiologists and nephrologists. METHODS: We collected data by radiologists from January 1, 2011 through December 31, 2011 and by nephrologists from since July 1, 2012 through June 30, 2013. We compared the duration from the hemodialysis decision to TDC placement (D-P duration) and hemodialysis initiation (D-H duration), catheter success and the complication rate, and the frequency and the usage time of non-tunneled hemodialysis catheters (NDCs) before TDC placement. RESULTS: The study analyzed 483 placed TDCs: 280 TDCs placed by radiologists and 203 by nephrologists. The D-P durations were 319 minutes (interquartile range [IQR], 180 to 1,057) in the radiologist group and 140 minutes (IQR, 0 to 792) in the nephrologist group. Additionally, the D-H durations were 415 minutes (IQR,260 to 1,091) and 275 minutes (IQR, 123 to 598), respectively. These differences were statistically significant (p = 0.00). The TDC success rate (95.3% vs. 94.5%, respectively; p = 0.32) and complication rate (16.2% vs. 11%, respectively; p = 0.11) did not differ between the groups. The frequency (24.5 vs. 26%, respectively; p = 0.72) and the usage time of NDC (8,451 vs. 8,416 minutes, respectively; p = 0.91) before TDC placement were not statistically significant. CONCLUSIONS: Trained interventional nephrologists could perform TDC placement safely, minimizing treatment delays.
Catheters*
;
Nephrology
;
Physical Examination
;
Renal Dialysis*
;
Vascular Access Devices

Result Analysis
Print
Save
E-mail